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Cabazitaxel shows a consistently greater survival benefit  
compared to mitoxantrone in patients with mCRPC
Johann S. de Bono1, Oliver Sartor2, Christine Geffriaud-Ricouard3,  
Florence Joulain3, Anders Widmark4
Aim. This sub analysis of TROPIC study evaluates overall survival (OS) under cabazitaxel in patients who had no initial 
response to docetaxel (D ) and discontinued D for disease progression and those who initially responded to D but 
experienced disease progression < 3 months since last D dose. These patients are believed unlikely to benefit from 
D re-treatment and need new treatment options such as cabazitaxel. 
Methods. Of the 755 patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TROPIC study, 
362 (47.9%) had no initial response to D and discontinued it for disease progression, 155 (20.5%) had an initial response 
to D therapy according to investigator judgment but progressed < 3 months since last D dose and 238 (31.5%) did 
not belong to these two subgroups. All patients were randomized to receive cabazitaxel 25 mg/m2 or mitoxantrone 
12 mg/m2 both every 3 weeks and prednisone 10 mg per os daily.
Results. Median OS with cabazitaxel was consistently longer than with mitoxantrone in all subgroups. The highest 
survival benefit versus mitoxantrone was observed for patients who initially responded to D and then progres-
sed < 3 months since last D dose (median OS 15.7 versus 11.6 months, Hazard ratio (HR) 0.52 [95% CI 0.35–0.76]). 
Median PFS was also significantly improved in the latter subgroup compared to mitoxantrone (2.6 versus 1.4 months, 
HR 0.66 [0.48–0.91]).
Conclusion. Cabazitaxel plus prednisone consistently shows a greater survival benefit compared to mitoxantrone 
plus prednisone whatever the subgroup considered, including responders to first-line D who progressed < 3 months 
since last D and pts without initial response to D who discontinued it for disease progression.
Kabazytaksel konsekwentnie wykazuje poprawę czasu przeżycia w porównaniu 
z mitoksantronem u chorych z opornym na kastrację, przerzutowym rakiem gruczołu krokowego 
(metastatic castration-resistant prostate cancer, mCRPC)
Cel. Niniejsza analiza — wtórna do badania TROPIC — ma na celu ocenę czasu przeżycia całkowitego (overall survival, 
OS) po zastosowaniu kabazytakselu w podgrupach chorych, u których od początku nie uzyskano odpowiedzi na 
docetaksel (D) i odstawiono docetaksel D z powodu progresji choroby, oraz u chorych, u których uzyskano począt-
kowo odpowiedź na D, lecz u których wystąpiła progresja nowotworu w czasie < 3 miesiące od ostatniej dawki D. 
U takich pacjentów uzyskanie korzyści z ponownego leczenia D jest mało prawdopodobne, dlatego też potrzebują 
oni nowych opcji terapeutycznych, takich jak kabazytaksel.
Metody. Z 755 chorych z przerzutami raka gruczołu krokowego opornego na kastrację (metastatic castration- 
-resistant prostate cancer, mCRPC), włączonych do badania TROPIC, u 362 (47,9%) nie zaobserwowano początkowej 
odpowiedzi na D i przerwano jego podawanie. U 155 (20,5%) — w ocenie badacza — obserwowano początkowo od-
powiedź na leczenie D, lecz wystąpiła progresja w czasie < 3 miesiące od ostatniej dawki D, a 238 (31,5%) nie należało 
do żadnej z tych podgrup. Wszystkich pacjentów zrandomizowano do grup otrzymujących kabazytaksel w dawce 
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225 mg/m2 lub mitoksantron w dawce 12 mg/m2 podawanych dożylnie co 3 tygodnie oraz prednizon, przyjmowany 
doustnie w dawce 10 mg/dzień. 
Wyniki. W każdej z podgrup mediana czasu przeżycia całkowitego (OS) dla chorych otrzymujących kabazytaksel była 
zawsze większa niż w grupie otrzymującej mitoksantron. Największą korzyść wydłużenia czasu przeżycia całkowitego 
w porównaniu z grupą otrzymującą mitoksantron obserwowano w podgrupie chorych, u których początkowo zaob-
serwowano odpowiedź na D, a następnie progresję w czasie < 3 miesiące od ostatniej dawki D {mediana 15,7 miesiąca 
w porównaniu z 11,6 miesiąca, współczynnik ryzyka HR (hazard ratio) 0,52; 95% przedział ufności CI (confidence interval) 
[0,35–0,76]}. Mediana czasu przeżycia wolnego od progresji była także znacząco lepsza w tej podgrupie w porównaniu 
z grupą otrzymującą mitoksantron (2,6 miesiąca w porównaniu z 1,4 miesiąca, HR 0,66 (0,48–0,91).
Wniosek. Kabazytaksel w skojarzeniu z prednizonem wykazuje konsekwentnie korzystniejsze działanie na czas prze-
życia w porównaniu z leczeniem mitoksantronem w skojarzeniu z prednizonem w każdej z podgrup, w szczególności 
u chorych, u których zaobserwowano odpowiedź na D zastosowany w pierwszej linii i u których doszło do progresji 
w czasie < 3 miesiące od ostatniej dawki D, a także u chorych bez początkowej odpowiedzi na D, którzy przerwali 
jego przyjmowanie w celu kontroli progresji choroby.
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Introduction
All patients with metastatic castration-resistant prostate 
cancer (mCRPC) eventually progress during or following 
first-line docetaxel therapy and until recently, second-line 
treatment approaches have been limited. Within the last 
three years, novel therapies able to prolong survival in the 
post-docetaxel setting have emerged, including the novel 
semi-synthetic taxane cabazitaxel [1–5]. The challenge for 
physicians is now to integrate this broad armamentarium 
rationally in daily practice and appropriately tailor therapy 
to optimize treatment outcomes and benefits of each indi-
vidual patient. Prostate cancer is a heterogeneous disease 
[6–8] and optimal treatment of mCRPC will involve better 
classification of the disease based on the androgen-sen-
sitivity status and underlying molecular mechanisms of 
progression [9]. 
Taxanes have an important place in mCRPC manage-
ment. By stabilizing microtubule spindle, they inhibit cell 
division and also contribute to inhibit ligand-dependent 
and ligand–independent AR nuclear translocation which 
is mediated by microtubules [10]. Cabazitaxel is a next ge-
neration taxane selected for clinical development based on 
its ability to overcome taxane resistance in vitro and in vivo 
and its activity in docetaxel-sensitive and docetaxel-resi-
stant cell lines and tumor models [11]. In addition, unlike 
docetaxel and paclitaxel, cabazitaxel has demonstrated the 
ability to cross the blood-brain barrier in vivo [11]. Results 
of the randomized, multinational, phase III TROPIC trial 
(NCT00417079) comparing cabazitaxel with mitoxantrone 
in patients with mCRPC progressing during or after a do-
cetaxel-containing regimen have been reported [1]. A total 
of 755 patients were randomized to cabazitaxel (25 mg/m2; 
n = 378) plus prednisone (10 mg/day), or mitoxantrone 
(12 mg/m2; n = 377) plus prednisone, every three weeks. Ca-
bazitaxel significantly improved median overall survival (OS) 
compared to mitoxantrone (15.1 versus 12.7 months, hazard 
ratio [HR] 0.70; p < 0.0001), representing a 30% reduction in 
the relative risk of death. Updated results of TROPIC (figure 1) 
confirm the long-term survival benefit of cabazitaxel, with 
almost twice as many patients alive at 2 years compared to 
the active control arm mitoxantrone (odds ratio [OR] 2.11; 
95% CI 1.33–3.33) [12]. This survival benefit was associated 
with a significant improvement in progression-free survival 
(PFS), a composite end-point defined as time from randomi-
zation to either PSA progression, or tumor progression, or 
pain progression, or death (2.8 versus 1.4 months, HR 0.74; 
p < 0.0001) [1]. Cabazitaxel also significantly improved the 
objective response rate evaluated according to RECIST cri-
Figure 1. Cabazitaxel significantly improves overall survival 
compared to mitoxantrone in 755 mCRPC patients progressing 
during or after docetaxel — Updated results [12]. HR — hazard ratio; 
CI — confidence interval
3teria (14.4% versus 4.4%; p=0 .0005) and the PSA response 
rate (39.2% versus 17.8%; p = 0.0002) [1].
We examined the survival benefit observed in TROPIC 
trial with cabazitaxel according to prior response to doce-
taxel (D) treatment, in order to determine which patients 
have the greatest benefit of the drug.
Methods
Details of eligibility and exclusion criteria are provided in 
the primary publication [1]. In brief, men with mCRPC were 
eligible if they had documented disease progression during 
or after completion of docetaxel treatment. Patients were 
required to have an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0–2, no prior mitoxantrone 
therapy and no radiotherapy ≥ 40% of the bone marrow, 
Patients with measurable disease were required to have 
documented disease progression by Response Evaluation 
Criteria in Solid Tumors (RECIST). Patients with non-measu-
rable disease were required to have rising serum prostate-
-specific antigen (PSA) or the appearance of at least one new 
demonstrable radiographic lesion. Patients were stratified 
for disease measurability (measurable vs non-measurable) 
and ECOG performance status (0–1 versus 2). Physical exa-
mination and radiologic investigations, including computed 
tomography and bone scanning, were performed at base-
line, along with blood tests, including serum PSA. Pain was 
assessed with the McGill- present pain intensity (PPI) scale 
and analgesic use was derived from consumption normali-
zed to morphine equivalents. 
Treatment was continued for a maximum of ten cyc-
les. Patients were followed up until the cutoff date for ana-
lysis or until death (whichever occurred first). Prophylactic 
granulocyte colony-stimulating factor was not allowed du-
ring the first cycle, but was allowed at physicians’ discretion 
after first occurrence of either neutropenia lasting 7 days 
or more or neutropenia complicated by fever or infection.
In this post-hoc analysis of TROPIC trial, subgroups of 
interest were defined as follows: 
1. Patients without initial response to D who discontinued 
D for disease progression, according to physician judg-
ment (n = 362). 
2. Patients who responded first to D and then progres-
sed < 3 months after the last D dose (n = 155). Response 
to D was defined by a PSA decrease during D therapy 
without signs of radiological or clinical progression.
3. Patients who did not satisfy criteria of subgroups (1) and 
(2) (n = 238). This corresponds to patients with stable 
disease during D therapy who progressed after the last D 
dose, irrespective of the time (n = 131) and patients who 
responded first to D and the progressed ≥ 3 months 
after the last D dose (n = 107).
Overall survival was analyzed using the Kaplan-Meier 
method, and comparisons between treatment arms were 
performed using the log-rank test; Hazard Ratios (HRs) and 
95% confidence intervals (CIs) were calculated with a Cox 
proportional hazards model (for both primary and secon-
dary analyses). Overall survival data were censored at the 
last date the patient was known to be alive or at the analysis 
cutoff date, whichever was earliest.
Results
Clinical characteristics of the 755 mCRPC patients en-
rolled in TROPIC are provided according to prior D respon-
se in table I. In patients who initially responded to D and 
progressed < 3 months since last D dose, the percentage 
of patients with only one line of prior D was slightly higher 
(75%) compared to the other groups. Other clinical charac-
teristics were well balanced between subgroups. 
Cabazitaxel improved OS compared to mitoxantrone, 
irrespective of the subgroup (table II). Nevertheless, the 
highest survival benefit was observed for patients who 
initially responded to D and then progressed < 3 months 
since last D dose with a median OS 15.7 in cabazitaxel group 
versus 11.6 months in mitoxantrone group (HR 0.52, 95% 
CI [0.35–0.76]) (figure 2). Median PFS was also significan-
tly improved in the subgroup compared to mitoxantrone 
(2.6 versus 1.4 months, HR 0.66 [0.48–0.91]).
The safety profile of cabazitaxel in TROPIC study has 
been reported previously [1]. In the TROPIC trial, the per-
centage of patients who discontinued treatment due to 
adverse events (AEs) was 18% in the cabazitaxel group com-
pared to 8% in the mitoxantrone group [1]. Grade ≥ 3 AEs 
in both treatment arms were primarily hematologic, with 
neutropenia (82% vs 58%), leucopenia (68% vs 42%), and 
febrile neutropenia (8% vs 1%) being higher with cabazitaxel 
compared to mitoxantrone (table III). The most common 
grade ≥ 3 nonhematologic AEs with cabazitaxel compared 
to mitoxantrone were diarrhea (6% vs < 1%), fatigue (5% vs 
3%) and asthenia (5% vs 2%). The rate of mortality within 
30 days of last drug infusion was 5% in the cabazitaxel arm, 
compared with 2% in the mitoxantrone arm. 
Discussion
This sub analysis of TROPIC study confirms that me-
dian OS with cabazitaxel is consistently greater than with 
mitoxantrone whatever the subgroup considered regarding 
response to docetaxel. The highest survival benefit ver-
sus mitoxantrone was observed for patients who initially 
responded to D and then progressed < 3 months since 
last D dose (HR 0.52, 95% CI [0.35–0.76]). Median PFS was 
also significantly improved in the subgroup compared to 
mitoxantrone (2.6 versus 1.4 months, HR 0.66 (0.48–0.91). 
Patients who had no initial response to D and discontinued 
it for disease progression also showed a significant benefit 
with cabazitaxel compared to mitoxantrone (HR 0.74, 95% CI 
[0.58–0.94]). These data support the efficacy of cabazitaxel 
in patients with either acquired or primary resistance to D. 
These results further confirm subgroup analyses of TROPIC 
4already published showing a consistent OS benefit with 
cabazitaxel compared to mitoxantrone [1, 12].
The fact that cabazitaxel is effective in patients with primary 
resistance to D is important because therapeutic options may 
be limited for such patients. Muckerji et al reported in a cohort 
of 44 men with CRPC treated with D followed by abiraterone 
at the Royal Marsden Hospital, that none of the 7 patients who 
were D refractory had a subsequent PSA, radiological or clinical 
response with abiraterone [13]. Similarly, patients developing 
acquired resistance to D also represent an unmet need. Hence, 
in patients with initial good response to D who progressed in 
less than 3 months after having stopped therapy, D rechallenge 
seems associated with marginal PSA and clinical responses and 
more importantly no OS benefit has been demonstrated with 
such a treatment option [14, 15]. The efficacy of abiraterone in 
such a population has not been documented.
Figure 2. Cabazitaxel significantly improves overall survival 
compared to mitoxantrone in 155 mCRPC patients with initial 
response to prior D and progression < 3 mo since last D dose
Table I. Clinical characteristics of patients according to prior response to D
Overall population No initial D response and 
progression during D
Initial D response and 
progression < 3 mo after 
last D dose
Remaining 
patients
MP 
(n = 377)
CBZP 
(n = 378)
MP 
(n = 183)
CBZP 
(n = 179)
MP 
(n = 78)
CBZP 
(n = 77)
MP 
(n = 183)
CBZP 
(n = 179)
Median age (years) 67.0 68.0 67.0 67.0 65.5 67.0 67.0 69.0
ECOG Performance Status 0–1 91.2% 92.6% 88.5% 91.1% 92.3% 93.5% 94.8% 94.3%
Tumor location
Bone  87%  80.2%  85.8% 76.5% 93.6%  88.3%  84.5% 80.3%
Lymph nodes 44.8% 45% 49.7% 44.7% 37.2% 40.3% 42.2% 48.4%
Visceral 24.9% 24.9% 29% 24% 20.5% 22.1% 21.6% 27.9%
Baseline PSA (ng/ml) — median 127.5 143.9 172.1 144.1 122.0 192.8 91.0 119.0
Measurable disease 54.1% 53.2% 58.5% 54.7% 47.4% 49.4% 51.7% 53.3%
Pain at baseline 44.6% 46% 45.9% 49.2% 47.4% 44.2% 40.5% 42.6%
N prior chemotherapy regimen
1 regimen 71.1% 68.8% 70.5% 67% 76.9% 74% 68.1% 68%
2 regimens 21% 24.9% 21.9% 27.4% 17.9% 16.9% 21.6% 26.2%
3 or more regimens 8% 6.3% 7.7% 5.6% 5.1% 9.1% 10.3% 5.7%
D — docetaxel; MP — mitoxantrone plus prednisone; CBZP — cabazitaxel plus prednisone
Table II. Overall survival with cabazitaxel and mitoxantrone according to prior response to D
MP CBZP CBZP vs MP
Patients Number  
dead/N (%)
Median OS  
[95% CI]
Number  
dead/N (%)
Median OS 
 [95% CI]
Hazard Ratio  
[95% CI]
Whole TROPIC population (ITT) 279/377 
(74%)
12.7 
[11.6-13.7]
234/378 
(61.9%)
15.1 
[14.1–16.3]
0.70 
[0.59–0.83]
Patients with no initial response to D  
who discontinued D for disease progression  
(subgroup [1])
149/183  
(81.4%)
10.3  
[9.0–12.7]
124/179  
(69.3%)
13.6  
[11.3–14.5]
0.74 
[0.58–0.94]
Patients with initial response to D and who 
progressed < 3 months after the last D dose  
(subgroup [2])
60/78 
 (76.9%)
11.6  
[9.8–13.7]
47/77 
 (61.0%)
15.7  
[13.4–21.9]
0.52 
[0.35–0.76]
Remaining patients (excluding [1] + [2]) 70/116 
 (60.3%)
16.4  
[15.1–19.3]
63/122  
(51.6%)
18.0  
[15.3–28.7]
0.74  
[0.52–1.05]
D — docetaxel; MP — mitoxantrone plus prednisone; CBZP — cabazitaxel plus prednisone; OS — overall survival; CI — confidence interval
5Several mechanisms have been involved in resistance to 
D. The first one is an overexpression of membrane-bound 
efflux proteins resulting in decreased cellular drug accumu-
lation: indeed some men with CRPC exhibit an overexpres-
sion of the ATP-binding cassette transporter P-glycoprotein 
(P-gp) [16, 17]. Another possible mechanism is the aberrant 
expression of tubulin isotypes, in particular beta-III tubulin 
or microtubule-regulating proteins [18]: expression of beta-
-III tubulin is increased by androgen deprivation in prostate 
cancer patients and appears to be associated with progres-
sion to castration resistance [19]. Overexpression of beta-III 
tubulin has been shown to be an independent predictor of 
OS in men with mCRPC treated with D, and in vitro mani-
pulations of beta-III tubulin can reverse resistance to D [20]. 
Changes in actin regulation can also mediate resistance to 
tubulin-binding agents [19]. Defects in apoptotic pathways 
may also be associated in resistance to D: during treatment 
with D, prostate cancer cells can activate antistress and 
antiapoptotic mechanisms (eg, Bcl-2, survivin, clusterin) 
that promote survival [21–23]. Hypoxia may also confer 
resistance to chemotherapy but may also select for tumor 
cells with a more malignant phenotype [25]. 
Lastly, it is important to consider that most fatal ad-
verse events possibly related to cabazitaxel in TROPIC trial 
occurred at the beginning of the recruitment phase and 
were attributed to lack of proactive management of ad-
verse events (mainly neutropenia and diarrhea) [26]. The 
importance of adequate patient care to optimize treatment 
benefits was highlighted by a sub-analysis of TROPIC limited 
to French centers [27]. Proactive management of adverse 
events was associated with a lower rate of discontinuation 
due to adverse events with cabazitaxel than in the global 
Table III. Adverse Events in the TROPIC Trial [2]
Selected Adverse Events,a  
n (%)
MP (n = 371) CBZP (n = 371)
All grades Grade ≥ 3 All Grades Grade ≥ 3
Hematologic
Neutropenia 325 (88%) 215 (58%) 347 (94%) 303 (82%)
Leukopenia 343 (92%) 157 (42%) 355 (96%) 253 (68%)
Anemia 302 (81%) 18 (5%) 361 (97%) 39 (11%)
Febrile neutropenia – 5 (1%) – 28 (8%)
Nonhematologic
Diarrhea 39 (11%) 1 (< 1%) 173 (47%) 23 (6%)
Fatigue 102 (27%) 11 (3%) 136 (37%) 18 (5%)
Asthenia 46 (12%) 9 (2%) 76 (20%) 17 (5%)
Back pain 45 (12%) 11 (3%) 60 (16%) 14 (4%)
Nausea 85 (23%) 1 (< 1%) 127 (34%) 7 (2%)
Vomiting 38 (10%) 0 84 (23%) 7 (2%)
Hematuria 14 (4%) 2 (1%) 62 (17%) 7 (2%)
Abdominal pain 13 (4%) 0 43 (12%) 7 (2%)
aSorted by decreasing frequency of grade ≥ 3 events in the CBZP arm. CBZP — cabazitaxel + prednisone; MP — mitoxantrone + prednisone
study population (11% versus 18%) and there was no toxic 
death, resulting in a greater OS benefit versus mitoxantro-
ne (+3.7 versus +2.4 months). A large compassionate use 
programme which included an awareness programme on 
proactive management of adverse events confirmed that 
toxicity of cabazitaxel was manageable in real life practice, 
including in older patients (≥ 70 year-old) with a much lower 
incidence of grade ≥ 3 toxicities and discontinuation for 
adverse events than in TROPIC trial [28, 29]. Of note, it also 
confirmed that cabazitaxel was associated with a particularly 
low rate of grade ≥ 3 neuropathy and nail disorders (< 1% 
for both) which are particularly bothersome for the patients.
Conclusion 
This sub analysis of TROPIC study, cabazitaxel plus pred-
nisone consistently shows a greater survival benefit compa-
red to mitoxantrone plus prednisone whatever the subgro-
up considered, including patients without initial response 
to D who discontinued it for disease progression. Patients 
responding to first-line D who progressed < 3 months since 
last D showed an excellent benefit with cabazitaxel.
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II Konkurs na projekty naukowe w zakresie badań podstawowych w onkologii
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